25 Jul 2017

Case Analysis : Japan’s Mitsubishi Tanabe’s acquisition of Israeli drug maker Neuroderm for $1.1 billion

Posted Byadmin

Comments0

Japan’s Mitsubishi Tanabe Pharma Corp has agreed to acquire Israeli drug maker Neuroderm for $1.1 billion in cash as part of a strategy to grow its business in the United States.

Reason for this acquisition:

1. This acquisition will help Japan’s Mitsubishi Tanabe Pharma Corp to stregthen its business in the United States.
2. Mitsubishi Tanabe Pharma Corp will be able to get access of Neuroderm’s Parkinson’s disease drug that is in advanced clinical trials in the United States and Europe and is expected to go on sale in the 2019 financial year.

Neuroderm is developing drug-device combinations for central nervous system disorders and its lead product is ND0612 for the treatment of Parkinson’s disease. Neuroderm has said its goal is to submit regulatory applications for ND0612 in Europe by the end of 2018.

Learn Inlicensing and Outlicensing in pharmaceutical Industry >> Learn More